Skip to Main Content

Paper Details

A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.
Mod Pathol
48
2019
CDX2, CK20, CK7, PAX8, Primary ovarian mucinous tumors, SATB2, appendiceal neoplasms, borderline mucinous tumors, borderline tumors, carcinomas, colorectal adenocarcinomas, colorectal and appendiceal metastases, metastatic gastrointestinal neoplasms, metastatic lower gastrointestinal tumor, mucinous carcinomas, ovarian endometrioid carcinoma, ovarian mucinous tumors, ovarian primary mucinous tumors, ovarian tumors, patients, primary lower gastrointestinal neoplasms, tumor, tumor cells
Author NameAffiliation
Maria P IntermaggioUniversity of NSW Sydney
Maria P IntermaggioAdult Cancer Program. Lowy Cancer Research Centre
Maria P IntermaggioUniversity of NSW Sydney
Maria P IntermaggioAdult Cancer Program. Lowy Cancer Research Centre
David G HuntsmanVancouver General Hospital, BC Cancer Agency and University of British Columbia
David G HuntsmanUniversity of British Columbia
David G HuntsmanBC Cancer Agency Research Centre
David G HuntsmanVancouver General Hospital, BC Cancer Agency and University of British Columbia
David G HuntsmanBC Cancer Agency Research Centre
David G HuntsmanUniversity of British Columbia
Lynne R WilkensUniversity of Hawaii Cancer Center
Lynne R WilkensUniversity of Hawaii Cancer Center
Helen SteedDivision of Gynecologic Oncology. Royal Alexandra Hospital
Esther HerpelTissue Bank of the National Center for Tumor Diseases, University of Heidelberg
Esther HerpelInstitute of Pathology, University Hospital Heidelberg
Michael S AnglesioUniversity of British Columbia
Michael S AnglesioUniversity of British Columbia
Jan LubinskiPomeranian Medical University
Jan LubinskiPomeranian Medical University
Ellen L GoodeDivision of Epidemiology. Mayo Clinic
Usha MenonMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London
Usha MenonMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London
Aleksandra To??oczko-GrabarekPomeranian Medical University
Oleg OszurekInternational Hereditary Cancer Center, Pomeranian Medical University
Aline TalhoukVancouver General Hospital, BC Cancer Agency and University of British Columbia
Montserrat Garcia-ClosasDivision of Cancer Epidemiology and Genetics. National Cancer Institute
Montserrat Garcia-ClosasInstitute of Cancer Research
Montserrat Garcia-ClosasDivision of Cancer Epidemiology and Genetics. National Cancer Institute
Montserrat Garcia-ClosasInstitute of Cancer Research
Catherine J KennedyThe Westmead Institute for Medical Research, The University of Sydney
Catherine J KennedyWestmead Hospital
Mercedes Jimenez-LinanDepartment of Histopathology. Addenbrookes Hospital
Janusz MenkiszakPomeranian Medical University
Marc T GoodmanSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Marc T GoodmanCommunity and Population Health Research Institute, Cedars-Sinai Medical Center
Stacey J WinhamDivision of Biomedical Statistics and Informatics. Mayo Clinic
Sabine BehrensGerman Cancer Research Center (DKFZ)
Jacek GronwaldPomeranian Medical University
Jacek GronwaldPomeranian Medical University
Brenda Y HernandezUniversity of Hawaii Cancer Center
Linda E KelemenMedical University of South Carolina
Gary L KeeneyDivision of Anatomic Pathology. Mayo Clinic
Michael E CarneyJohn A. Burns School of Medicine, University of Hawaii
Raghwa SharmaWestmead Hospital, The University of Sydney
Raghwa SharmaUniversity of Western Sydney at Westmead Hospital
Simon A GaytherKeck School of Medicine, University of Southern California
Simon A GaytherCenter for Cancer Prevention and Translational Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Simon A GaytherCedars-Sinai Medical Center
Jennifer AlsopUniversity of Cambridge
Hugh LukUniversity of Hawaii Cancer Center
  • 1 - 50

Datasets